The Use of Liposomal Bupivacaine in TAP Blocks for Women Undergoing Cesarean Section

Withdrawn before enrolling · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Pain

In brief

This present investigation aims to determine whether a transversus abdominous plane(TAP) block, utilizing liposomal bupivacaine (Exparel), at the conclusion of a cesarean section decreases post-operative pain. The hypothesis is that performance of the TAP block with liposomal bupivacaine will decrease post-operative narcotic use.

Key facts

Study ID

NCT02847013

Run by

Milton S. Hershey Medical Center

People needed

0

Last updated by the study team

2020-01-31

Who can join

Age: 18 and older, up to 55. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Patients >18 years of age
• Scheduled cesarean section with or without bilateral tubal ligation
• Planned performance of a Pfannenstiel incision
• Patients are schedule to have a cesarean section with a member of the Women's Health or Maternal and Fetal Medicine Departments at Penn State University Hershey S. Medical Center

You may not qualify if…

• History of opioid use
• History of chronic pain syndrome
• Use of general anesthesia during cesarean delivery
• Postoperative SICU admission
• Postpartum hemorrhage (defined as an Estimated Blood Loss of greater then 1,000mL upon completion of the cesarean section)

Where it is running

• Milton S. Hershey Medical Center — Hershey, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.